Trial Profile
A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Antipsychotics
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 20 Jul 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 19 Jul 2021 Planned End Date changed from 1 May 2021 to 31 Dec 2023.
- 19 Jul 2021 Planned primary completion date changed from 1 Nov 2020 to 31 Dec 2022.